IP Library Granted Patent US 10,683,262
Granted Patent B2
US 10,683,262 · App. 16/502,562 · Granted Jun 16, 2020

Ketamine derivatives and compositions thereof

Inventors: Jia-Ning Xiang (Hubei, CN); Xuesong Xu (Hubei, CN); Hao-Wei Shih (New Taipei, TW); Wai-si Eng (Maple Glen, PA)
Assignee: XW LABORATORIES INC.
C07C271/24A61K9/0053C07C211/35C07C271/56C07D207/16C07D207/28C07D211/62C07D213/80C07D305/06C07D309/08C07D317/68
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,683,262
App. No.
16/502,562
Granted
Jun 16, 2020
Kind
B2
Abstract

Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.

Claims (122)

1. A compound of Formula (1):

or a pharmaceutically acceptable salt thereof, wherein,

R 1 is selected from hydrogen and C 1-6 alkyl; and

R 2 is selected from a moiety of Formula (2), a moiety of Formula (3), a moiety of Formula (4), and a moiety of Formula (5):

wherein,

R 3 is selected from hydrogen, C 1-6 alkyl, C 7-12 alkylarene, and substituted C 7-12 alkylarene;

R 4 is selected from hydrogen and C 1-6 alkyl;

R 5 is selected from hydrogen, C 1-6 alkyl, —C(═O)R 10 , and —C(═O)—OR 10 ,

wherein R 10 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and —CF 3 ;

R 6 is selected from C 1-6 alkyl and C 1-6 alkoxy;

n is an integer from 0 to 3;

R 7 is selected from C 1-6 alkyl, —C(═O)—R 11 and —C(═O)—O—R 10 ,

wherein,

R 10 is selected from C 1-6 alkyl and C 3-6 cycloalkyl; and

R 11 is selected from —NH 2 , —CF 3 , C 1-6 alkyl, and C 3-6 cycloalkyl; and

R 9 is selected from hydrogen and C 1-3 alkyl.

2. The compound of claim 1 , wherein R 2 is a moiety of Formula (2):

3. The compound of claim 1 , wherein R 2 is a moiety of Formula (3):

4. The compound of claim 1 , wherein the moiety of Formula (3) has the structure of Formula (3a):

5. The compound of claim 1 , wherein R 2 is a moiety of Formula (4):

6. The compound of claim 1 , wherein R 2 is a moiety of Formula (5):

7. The compound of claim 6 , wherein R 7 is selected from and C 1-3 alkyl.

8. The compound of claim 1 , wherein the compound is the (R)-isomer having the structure of Formula (1a):

9. The compound of claim 1 , wherein the compound is the (9-isomer having the structure of Formula (1b):

10. The compound of claim 1 , wherein the compound is selected from:

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (3);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl (tert-butoxycarbonyl)glycinate (4);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl (tert-butoxycarbonyl)-L-valinate (5);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (6);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alaninate (7);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-valinate (8);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 1-methylpiperidine-4-carboxylate (17);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl isobutyrylglycinate (19);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (22);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)propyl 2-(3-methyloxetan-3-yl)acetate (24);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)-2-methylpropyl 2-(3-methyloxetan-3-yl)acetate (26);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)propyl acetylglycinate (27);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)-2-methylpropyl acetylglycinate (28);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetylglycinate (31);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-valinate (32);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-alaninate (33);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl isobutyrylglycinate (34);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl isobutyryl-L-alaninate (35);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl isobutyryl-L-valinate (36);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl L-valinate (37);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl glycinate (38),

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-L-valinate (39);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl N-acetyl-N-methylglycinate (40);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl N-acetyl-N-methylglycinate (41);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl propionylglycinate (42);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl propionylglycinate (43);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl L-alaninate (44);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl (2,2,2-trifluoroacetyl)glycinate (45);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl (2,2,2-trifluoroacetyl)glycinate (46);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl dimethyl-L-alaninate (47);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl (2,2,2-trifluoroacetyl)-L-valinate (48);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)propyl (2,2,2-trifluoroacetyl)glycinate (49);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl (2,2,2-trifluoroacetyl)-L-alaninate (50);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)-2-methylpropyl (2,2,2-trifluoroacetyl)glycinate (51);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl (2,2,2-trifluoroacetyl)-L-valinate (52);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl (2,2,2-trifluoroacetyl)-L-alaninate (53);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (57);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-leucinate (58);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (59);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-alloisoleucinate (60);

1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (62);

1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (63);

1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alaninate (64);

1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-valinate (65);

(R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (66);

(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetylglycinate (68);

(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-valinate (69);

(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-alaninate (70);

((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-leucinate (71);

(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-alloisoleucinate (72);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-L-lloisoleucinate hydrogen chloride (74);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl methyl-L-valinate hydrogen chloride (75);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl di methyl-L-leucinate hydrogen chloride (76);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl di ethyl-L-valinate hydrogen chloride (77);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl methyl-L-alaninate 2,2,2-trifluoroacetic acid (78);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dipropyl-L-valinate (79);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl L-leucinate hydrogen chloride (80);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl isopropyl-L-valinate hydrogen chloride (81);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl propyl-L-valinate hydrogen chloride (82);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl ethyl-L-valinate (83);

(piperidine-4-carboxyloyloxy)methyl (5)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (86);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-D-prolinate (87);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-phenylalaninate (88);

((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl acetyl-L-tyrosinate (89);

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl dimethyl-L-valinate (90); and

a pharmaceutically acceptable salt of any of the foregoing.

11. The compound of claim 1 , wherein,

R 1 is selected from hydrogen and methyl;

R 2 is a moiety of Formula (2);

R 3 is selected from hydrogen and C 1-4 alkyl;

R 4 is selected from hydrogen and C 1-3 alkyl; and

R 5 is selected from C 1-3 alkyl and —C(═O)R 10 , wherein R 10 is selected from C 1-3 alkyl.

12. The compound of claim 1 , wherein,

R 1 is selected from hydrogen and methyl;

R 2 is a moiety of Formula (4);

n is 1; and

R 9 is selected from C 1-3 alkyl.

13. The compound of claim 1 , wherein,

R 1 is selected from hydrogen and methyl;

R 2 is a moiety of Formula (5); and

R 7 is selected from C 1-3 alkyl.

14. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition comprises an oral dosage form.

16. The pharmaceutical composition of claim 15 , wherein the oral dosage form comprises a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof for treating depression of a patient.

17. A method of providing a therapeutically effective concentration of ketamine in a patient's blood for treating depression comprising administering to the patient in need thereof, the compound of claim 1 or a pharmaceutically acceptable salt thereof.

18. The method of claim 17 , wherein administering comprises orally administering.

19. A method of treating depression in a patient comprising administering to a patient in need thereof, a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

20. The method of claim 19 , wherein administering comprises orally administering.

21. The method of claim 19 , wherein, following administration, the compound provides a therapeutically effective amount of (R)-ketamine, (S)-ketamine, a metabolite of any of the foregoing, or a combination of any of the foregoing in the patient's blood for treating depression.

22. The compound of claim 1 , wherein the compound is (S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (22):

23. The compound of claim 1 , wherein the compound is ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-L-valinate (39):

24. The compound of claim 1 , wherein the compound is (R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (66):

25. The compound of claim 1 , wherein, the compound is the (R)-isomer having structure of Formula (1a);

R 1 is hydrogen;

R 2 is a moiety of Formula (2);

R 3 is isopropyl and the carbon atom to which R 3 is bonded is in the (S) configuration; and

each of R 4 and R 5 is methyl.

Assignments (2)
CHANGE OF NAME Recorded May 4, 2021
From: XW LABORATORIES INC.
To: XWPHARMA LTD.
Reel/Frame 056177/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2019
From: XIANG, JIA-NING; XU, XUESONG; SHIH, HAO-WEI; ENG, WAI-SI
To: XW LABORATORIES INC.
Reel/Frame 050804/0887 →
Continuity (3)
Continuation PCTCN2019070912 · Jan 8, 2019
Provisional Application 62615948 · Jan 10, 2018
Related Publication 20190322618A1 · Oct 24, 2019
Cited By (15)
US 12,186,296 US 12,186,298 US 12,226,377 US 12,226,388 US 12,226,389 US 12,239,625 US 12,257,223 US 12,263,150 US 12,263,151 US 12,295,926 US 12,303,478 US 12,478,604 US 12,551,457 US 12,558,324 US 12,655,089